Annals of Military and Health Sciences Research

Published by: Neoscriber Demo Publisher

Evaluation of Apoptosis and Neuronal Changes in the Compact Part of Substantia Nigra and Striatum Following the Use of Levodopa and Levodopa -Benserazide in Parkinson’s Rats

Mahmood Reza Madadian 1 , Manouchehr Safari 2 , Laya Ghahari 1 , * and Katayoun Safari 3
Authors Information
1 Department of Anatomy, AJA University of Medical Sciences, Tehran, Iran
2 Department of Anatomy, Semnan University of Medical Sciences, Semnan, Iran
3 Doctor of Veterinary Medicine, Tehran University, Tehran, Iran
Article information
  • Annals of Military and Health Sciences Research: September 2018, 16 (3); e84681
  • Published Online: October 31, 2018
  • Article Type: Research Article
  • Received: September 27, 2018
  • Revised: October 14, 2018
  • Accepted: October 14, 2018
  • DOI: 10.5812/amh.84681

To Cite: Madadian M R , Safari M, Ghahari L, Safari K. Evaluation of Apoptosis and Neuronal Changes in the Compact Part of Substantia Nigra and Striatum Following the Use of Levodopa and Levodopa -Benserazide in Parkinson’s Rats, Ann Mil Health Sci Res. 2018 ; 16(3):e84681. doi: 10.5812/amh.84681.

Abstract
Copyright © 2018, Annals of Military and Health Sciences Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Chen Y, Zhang DQ, Liao Z, Wang B, Gong S, Wang C, et al. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease. Mol Neurodegener. 2015;10:4. doi: 10.1186/1750-1326-10-4. [PubMed: 26013581]. [PubMed Central: PMC4506434].
  • 2. Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S189-94. doi: 10.1016/S1353-8020(09)70812-0. [PubMed: 20082988].
  • 3. Safari M, Jafari B, Zarbakhsh S, Sameni H, Vafaei AA, Mohammadi NK, et al. G-CSF for mobilizing transplanted bone marrow stem cells in rat model of Parkinson's disease. Iran J Basic Med Sci. 2016;19(12):1318-24. doi: 10.22038/ijbms.2016.7918. [PubMed: 28096964]. [PubMed Central: PMC5220237].
  • 4. Miller RL, James-Kracke M, Sun GY, Sun AY. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res. 2009;34(1):55-65. doi: 10.1007/s11064-008-9656-2. [PubMed: 18363100].
  • 5. Filomeni G, Graziani I, De Zio D, Dini L, Centonze D, Rotilio G, et al. Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: Possible implications for Parkinson's disease. Neurobiol Aging. 2012;33(4):767-85. doi: 10.1016/j.neurobiolaging.2010.05.021. [PubMed: 20594614].
  • 6. Picconi B, Paille V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, et al. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis. 2008;29(2):327-35. doi: 10.1016/j.nbd.2007.10.001. [PubMed: 17997101].
  • 7. Cho C, Osaki Y, Kunin M, Cohen B, Olanow CW, Raphan T. A model-based approach for assessing parkinsonian gait and effects of levodopa and deep brain stimulation. Conf Proc IEEE Eng Med Biol Soc. 2006;1:1228-31. doi: 10.1109/IEMBS.2006.259439. [PubMed: 17946882].
  • 8. Olanow CW, Obeso JA, Stocchi F. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol. 2006;2(7):382-92. doi: 10.1038/ncpneuro0222. [PubMed: 16932589].
  • 9. Fahn S; Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol. 2005;252 Suppl 4:IV37-42. doi: 10.1007/s00415-005-4008-5. [PubMed: 16222436].
  • 10. Wolters EC, Francot C, Bergmans P, Winogrodzka A, Booij J, Berendse HW, et al. Preclinical (premotor) Parkinson's disease. J Neurol. 2000;247 Suppl 2:II103-9. [PubMed: 10991655].
  • 11. Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem. 2006;99(2):381-92. doi: 10.1111/j.1471-4159.2006.04124.x. [PubMed: 16942598].
  • 12. Marras C, Lang AE. Outcome measures for clinical trials in Parkinson's disease: Achievements and shortcomings. Expert Rev Neurother. 2004;4(6):985-93. doi: 10.1586/14737175.4.6.985. [PubMed: 15853525].
  • 13. Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol. 2006;202(2):391-403. doi: 10.1016/j.expneurol.2006.07.001. [PubMed: 16908021].
  • 14. Meredith GE, Rademacher DJ. MPTP mouse models of Parkinson's disease: An update. J Parkinsons Dis. 2011;1(1):19-33. doi: 10.3233/JPD-2011-11023. [PubMed: 23275799]. [PubMed Central: PMC3530193].
  • 15. Zhang W, He H, Song H, Zhao J, Li T, Wu L, et al. Neuroprotective effects of salidroside in the MPTP mouse model of Parkinson's disease: Involvement of the PI3K/Akt/GSK3beta pathway. Parkinsons Dis. 2016;2016:9450137. doi: 10.1155/2016/9450137. [PubMed: 27738547]. [PubMed Central: PMC5050371 publication of this paper].
  • 16. Badban L, Safari M, Sameni HR, Bandegi AR, Vafaei AA, Pour Rashidy A, et al. Protective effects of water extract of propolis on dopaminergic neurons, brain derived neurotrophic factor and stress oxidative factors in the rat model of Parkinson’s disease. Int J Pharm. 2015;11(4):300-8. doi: 10.3923/ijp.2015.300.308.
  • 17. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 1997;77(4):1037-48. [PubMed: 9130785].
  • 18. Guo G, Xu S, Cao LD, Wu QY. The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia. Eur Rev Med Pharmacol Sci. 2016;20(11):2409-12. [PubMed: 27338068].
  • 19. Sarrafchi A, Bahmani M, Shirzad H, Rafieian-Kopaei M. Oxidative stress and Parkinson's disease: New hopes in treatment with herbal antioxidants. Curr Pharm Des. 2016;22(2):238-46. [PubMed: 26561062].
  • 20. Tanriover G, Seval-Celik Y, Ozsoy O, Akkoyunlu G, Savcioglu F, Hacioglu G, et al. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease. Folia Histochem Cytobiol. 2010;48(3):434-41. doi: 10.2478/v10042-010-0047-6. [PubMed: 21071351].
  • 21. von Wrangel C, Schwabe K, John N, Krauss JK, Alam M. The rotenone-induced rat model of Parkinson's disease: Behavioral and electrophysiological findings. Behav Brain Res. 2015;279:52-61. doi: 10.1016/j.bbr.2014.11.002. [PubMed: 25446762].
  • 22. Alirezaei M. Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats. Iran J Basic Med Sci. 2015;18(10):950-7. [PubMed: 26730328]. [PubMed Central: PMC4686578].
  • 23. Puspita L, Chung SY, Shim JW. Oxidative stress and cellular pathologies in Parkinson's disease. Mol Brain. 2017;10(1):53. doi: 10.1186/s13041-017-0340-9. [PubMed: 29183391]. [PubMed Central: PMC5706368].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments